Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015637 | 0.81 | PTGER1 (0.41) | ALDH1A1PTGER1NPC1MAPTRAB9A | |
| SCHEMBL30250811 | 0.74 | PTGER1 (0.40) | ALDH1A1HPGDHSD17B10PTGER1NPC1 | |
| SCHEMBL2425146 | 0.72 | CYP2C9 (0.50) | PTGS2PTGS1HPGDHSD17B10NPC1 | |
| SCHEMBL30250467 | 0.71 | ALDH1A1 (0.47) | PTGS2PTGS1ALDH1A1HSD17B10PTGER1 | |
| SCHEMBL11333368 | 0.71 | HPGD (0.48) | ALDH1A1HPGDHSD17B10NPC1MAPT | |
| SCHEMBL5013553 | 0.70 | PTGS2 (0.54) | PTGS2PTGS1ALDH1A1PTGER1NPC1 | |
| SCHEMBL17620668 | 0.70 | ALDH1A1 (0.47) | PTGS2PTGS1ALDH1A1HPGDPTGER1 | |
| SCHEMBL11314026 | 0.66 | RAB9A (0.39) | PTGS2PTGS1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL17621095 | 0.65 | BRPF1 (0.51) | PTGS2PTGS1ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL17620981 | 0.65 | MAPK1 (0.40) | PTGS2PTGS1ALOX15NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | claimed |
| EP-1773331-A1 | IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-18 | — | — | EP | claimed |
| WO-2006008556-A1 | IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-01-26 | — | — | WO | claimed |
| WO-2008127613-A1 | NEW PHARMACEUTICAL COMPOSITIONS | SCYNEXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | SCYNEXIS, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-10-09 | — | — | US | disclosed |
| EP-1773331-A1 | IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008556-A1 | IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255038-A1 | 3-[(R)-2-(N,N-dimethylamino)ethylthio-Sar]-4-(gamma-hydroxymethylleucine)cyclosporin, for example, and pharmaceutical compositions prepared from the same, in combination with one or more NS5B polymerase inhibitors; use in treatment of hepatitis C virus; avoids need to use interferon or ribavirin | NSUN2, TPMT, EIF5B | PTGS2 3442/4885PTGS1 3116/4885ALDH1A1 3196/4885 |
| US-20080249146-A1 | Imidazole and Thioazole Derivatives as Antiviral Agents | IRF3, HAVCR2, ZC3HAV1 | PTGS2 1565/4885PTGS1 602/4885ALDH1A1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.